Nutex Health, Inc. (NUTX)
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-09-04
$193.24-2.25%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-09-04
Broken: Primary pillar broken — Achieve EPS of at least $21.52 in FY 2026 and $23.03 in FY 2027: FY2026 EPS guidance $15.87 vs target $21.52.
Nutex Health is growing profitably with operating income rising from $30.9M to $81.3M in one quarter. Analysts expect EPS to grow to $21.52 in 2026 and $23.03 in 2027. The stock trades cheaply at a PE of 9.24, well below peers. Free cash flow yield is positive, supporting a strong financial position.
The company faces legal and regulatory risks including a delisting notice and litigation. EPS guidance is soft for 2026, and revenue growth is modest at about 7%. High risk and mixed signals could pressure the stock if growth stalls or costs rise.
The market prices Nutex about 32% below our fair value near $277, reflecting about 7% revenue growth. Our view aligns with this justified discount given the company's growth and risk profile.
Breaks if: EPS falls below $15 in FY 2026 or below $18 in FY 2027
Breaks if: operating income falls below $30 million in any quarter after 2026-Q1
revenue growth falls below 5% YoY
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on growth through hospital expansion. The current thesis state is intact, supported by strong financial performance and a robust earnings quality.
The market currently prices NUTX as cheap compared to its peers, with a notable expectations gap. This suggests that investors may not fully account for the company's recent strong performance and growth potential.
Management is on track with improving profitability and operating income, as evidenced by significant gains in recent quarters. However, the mixed status of their growth strategy and EPS target indicates some uncertainty in execution.
Key factors include management's ability to maintain guidance and execute their growth strategy, as well as broader sector performance. The potential for economic downturns could also impact NUTX's performance if job reports continue to weaken.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports the view of improved profitability. This positive performance reinforces the outlook for operating income. There are no current threats to the thesis.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: PE rises above 20 without earnings growth
Overall, NUTX presents a compelling long-term thesis amid strong fundamentals, but investors should remain cautious of near-term risks. Not investment advice.